glp 1 drugs in development Upcoming wave of hormone-based therapies set to change field of diabetes, obesity care GLP-1-based therapies for diabetes, obesity

TK, IA and AL contributed to data acquisition

The mean differences between the treatment and placebo groups were approximately 12 centimeters across the two trials. The trials also reported: Mean trunk-fat reductions of approximately 0.81.0 kilograms Mean lean-body-mass increases of approximately 1.21.3 kilograms Little overall change in total body weight These results suggest that tesamorelin can alter the distribution of fat and lean tissue without functioning as a conventional weight-loss agent

Burke A, Fitzgerald GA

Until now, all GLP1 options for weight loss required injections

This is very important during pregnancy

The Phase 3 SURMOUNT trials, which enrolled over 6,000 participants, did not exclude patients taking antioxidant supplements (including glutathione precursors like N-acetylcysteine)